High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 6, 2007, Pages 2387-2390

  Wang, Yangang ^a,b   Hou, Peng ^a   Yu, Hongyu ^c   Wang, Wei ^b   Ji, Meiju ^a   Zhao, Shihua ^b   Yan, Shengli ^b   Sun, Xianlu ^b   Liu, Dingxie ^a   Shi, Bingyin ^d   Zhu, Guangwu ^b   Condouris, Stephen ^a   Xing, Michael Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QINGDAO UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN;

ARTICLE; DNA ISOLATION; DNA SEQUENCE; FOLLICULAR THYROID ADENOMA; FOLLICULAR THYROID CANCER; GENE MUTATION; GENETIC CORRELATION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; PAPILLARY THYROID CANCER; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; THYROID CANCER; THYROID TUMOR;

EID: 34347251976     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2019     Document Type: Article

References (22)

1. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
2. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
3. Ciampi R, Nikiforov YE 2005 Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16:163-172
4. Shinohara M, Chung YJ, Saji M, Ringel MD 2006 Akt in thyroid tumorigenesis and progression. Endocrinology 148:942-947
5. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M 2004 PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204
6. Bader AG, Kang S, Zhao L, Vogt PK 2005 Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5:921-929
7. Samuels Y, Ericson K 2006 Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77-82
8. Sansal I, Sellers WR 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963
9. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE 2004 High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
10. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693
11. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsen MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207
12. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752
13. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C 1997 Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713
14. Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Saji M, Westra WH, Zeiger MA, Jen J, Sidransky D 1998 Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23:239-243
15. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K, Taketani Y 2001 PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7:2636-2642
16. Konopka B, Paszko Z, Janiec-Jankowska A, Goluda M 2002 Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett 178:43-51
17. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
18. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL 2004 Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170:1088-1094
19. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW 2002 Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62:3636-3640
20. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD 2006 Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 118:1877-1883
21. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170
22. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77